They must know something, I am perplexed at the number of irons they are trying to keep burning as of late. Even $92MM can't get Cotara through phase 3 plus the Liver cancer trial now Pancreatic cancer and lung cancer , add HCV.
Let us not forget that Bavituximab, when "armed" with a radionuclide, functions as a radioimmunoconjugate, and in this configuration may well be a very effective monotherapy drug.
Something bigger seems to be going on here. I had assumed that we wouldn’t see any new bavi HCV trials. To me, it would of made more sense to start over with 11.31. They must be very confident that the results with bavi will still be good.
So why, when they’re still cash poor and have a bunch of other irons in the fire, do they see the need to take on HCV and Pancreatic Cancer?
News 
Market Data 
Discover 
AI
